Jean-Christophe Tellier, chief executive of Belgium's largest biotech, UCB, provides an op-ed on the UK life sciences.
In the context of ongoing discussions between government and industry over the UK's drug pricing framework, Dr Tellier argues that long-term investment is possible, as long as the right operational and commercial environment exists.
The UK is an attractive place to conduct life science research and development (R&D). However, we must caveat this statement with the words, ‘for now’.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze